Clinical Trial Update: A Multicenter Randomized Controlled Study on the Treatment of Refractory CTIT With Romiplostim N01 Compared to Recombinant Human Thrombopoietin [Phase 3]

View source ↗

Summary

A Phase 3 randomized trial comparing Romiplostim N01 to recombinant human thrombopoietin for refractory chemotherapy-induced thrombocytopenia, currently not rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chemotherapy-induced Thrombocytopenia

Drugs mentioned

• Romiplostim N01 (romiplostim)
• recombinant human thrombopoietin (recombinant human thrombopoietin)

Snippet

Sponsor: Shandong University | Conditions: CTIT-Chemotherapy Induced Thrombocytopenia | Phase 3 | Status: NOT_YET_RECRUITING